Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Virax Biolabs Group Limited (VRAX)

Virax Biolabs Group Limited (VRAX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Virax Biolabs Achieves ISO Certifications, Laying Foundation for Regulated IVD Development and U.S. Clinical Validation PR Newswire - Tue Mar 31, 6:34AM CDT

LONDON , March 31, 2026 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company") today announced that Virax Biolabs (UK) Limited, its wholly owned subsidiary, has achieved...

VRAX : 0.1740 (-12.12%)
Virax Biolabs Group Limited Announces Closing of $5 Million Private Placement PR Newswire - Thu Dec 4, 2025

LONDON , Dec. 4, 2025 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company dedicated to the advancement of immunology research...

VRAX : 0.1740 (-12.12%)
Virax Biolabs Group Limited Announces $5 Million Private Placement PR Newswire - Wed Dec 3, 2025

LONDON , Dec. 3, 2025 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company dedicated to the advancement of immunology research...

VRAX : 0.1740 (-12.12%)
Virax Biolabs' CEO James Foster Outlines Clinical Progress and 2026 Priorities in Latest Annual Letter to Shareholders PR Newswire - Wed Dec 3, 2025

Virax Biolabs' proprietary in-development diagnostic technology for post-acute infection syndromes ("PAIS"), such as Long COVID, positions the Company for an important data year ahead, following a series...

VRAX : 0.1740 (-12.12%)
Virax Biolabs Completes UK Clinical Recruitment and Reports Constructive FDA Feedback for ViraxImmune™ Study Evaluating T Cell Dysfunction in Post-Acute Infection Syndromes PR Newswire - Mon Nov 3, 2025

LONDON , Nov. 3, 2025 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on the detection of immune responses to and...

VRAX : 0.1740 (-12.12%)
Virax Biolabs Partners with Emory University on ViraxImmune™ Clinical Studies; Readies for FDA Pre-Submission Meeting in Early September PR Newswire - Tue Aug 26, 2025

LONDON , Aug. 26, 2025 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on immune response detection...

VRAX : 0.1740 (-12.12%)
Virax Biolabs Appoints Iain Miller, PhD as Independent Director to Accelerate Commercial Strategy PR Newswire - Tue Jul 29, 2025

LONDON , July 29, 2025 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company focused on the detection of immune responses...

VRAX : 0.1740 (-12.12%)
Virax Biolabs Announces Receipt of NASDAQ Notification Letter Regarding Minimum Bid Price Deficiency PR Newswire - Fri Jul 18, 2025

LONDON , July 18, 2025 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on the detection of immune responses...

VRAX : 0.1740 (-12.12%)
Virax Biolabs Group Announces Early-Access Program Launch of Research Use Only ViraxImmune Product and Hosts Webinar PR Newswire - Tue Sep 12, 2023

/PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative diagnostics company focused on the detection of immune...

VRAX : 0.1740 (-12.12%)
Virax Biolabs Group Appoints Dr. Nigel McCracken as Chief Operating Officer to Oversee Growth Momentum PR Newswire - Fri Sep 1, 2023

/PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative diagnostics company focused on the detection of immune...

VRAX : 0.1740 (-12.12%)

Barchart Exclusives

Sysco Just Announced a $29.1 Billion Acquisition and Wall Street Is Nervous. Can a 3% Dividend Sweeten the Deal? Barchart - Thu Apr 2, 6:30PM CDT
The Jetro deal strategically pushes Sysco into a faster‑growing, higher‑margin channel, but the new debt, jumping leverage, share dilution, and negative S&P outlook explain why SYY stock just had its worst day since 2020. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.